Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.567NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.541NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.24NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.25NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.189NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.563NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.34NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.258NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.426NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.399NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.337NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.539NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.35NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.54NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.164NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
KY.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JN.2.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.392NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.377NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.5.3 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BB.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.6.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FK.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HF.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.31NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HG.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.4.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.9.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDBNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.35NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GM.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.44NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FU.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FV.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.22.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FE.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBL.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.56NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.1.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.49NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBL.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used